Axsome Therapeutics, Inc.
AXSM
$210.63
$2.811.35%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 45.54% | 57.42% | 65.03% | 63.22% | 72.13% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 45.54% | 57.42% | 65.03% | 63.22% | 72.13% |
| Cost of Revenue | 0.86% | 50.42% | 17.26% | 41.19% | 66.95% |
| Gross Profit | 49.94% | 58.03% | 69.67% | 65.15% | 72.66% |
| SG&A Expenses | 59.76% | 53.16% | 49.46% | 57.21% | 25.81% |
| Depreciation & Amortization | 0.00% | 0.00% | 0.00% | 0.06% | -0.06% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 38.31% | 43.54% | 28.62% | 35.05% | 19.51% |
| Operating Income | -14.12% | -13.15% | 41.55% | 28.79% | 40.94% |
| Income Before Tax | -4.60% | -8.63% | 62.41% | 26.89% | 38.33% |
| Income Tax Expenses | 113.33% | -- | 405.88% | -- | -- |
| Earnings from Continuing Operations | -6.96% | -8.63% | 61.88% | 26.89% | 39.54% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.96% | -8.63% | 61.88% | 26.89% | 39.54% |
| EBIT | -14.12% | -13.15% | 41.55% | 28.79% | 40.94% |
| EBITDA | -13.35% | -13.24% | 43.33% | 30.92% | 42.39% |
| EPS Basic | -2.09% | -3.69% | 63.45% | 29.64% | 41.82% |
| Normalized Basic EPS | -7.78% | -5.43% | 44.14% | 32.03% | 41.84% |
| EPS Diluted | -2.09% | -3.69% | 63.45% | 29.64% | 41.82% |
| Normalized Diluted EPS | -7.78% | -5.43% | 44.14% | 32.03% | 41.84% |
| Average Basic Shares Outstanding | 4.77% | 4.76% | 4.30% | 3.91% | 3.93% |
| Average Diluted Shares Outstanding | 4.77% | 4.76% | 4.30% | 3.91% | 3.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |